Roche gains FDA nod for Wilserdly and De Novo authorization for cobas pro i 601
FROM THE WIRE · FINANCE.YAHOO.COM
Roche Holding (SWX:ROP) received US FDA approval for Wilserdly (giredestrant) as an oral therapy for advanced ER-positive, ESR1-mutated breast cancer. The decision supports use of Wilserdly as part of an all-oral SERD combination regimen for patients with hormone-resistant…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishApproval of an oncology drug and a diagnostic platform is relevant for a large healthcare group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved Wilserdly (giredestrant) for advanced ER-positive, ESR1-mutated breast cancer.
- 02The decision supports use in an all-oral SERD combination regimen.
- 03The FDA also granted De Novo authorization for the cobas pro i 601 platform.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets